Cargando…
Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer
BACKGROUND: Approximately 25% of patients with early-stage breast cancer experience cancer progression throughout the disease course. Alterations in TMEM240 in breast cancer were identified and investigated to monitor treatment response and disease progression. METHODS: Circulating methylated TMEM24...
Autores principales: | Lin, Ruo-Kai, Su, Chih-Ming, Lin, Shih-Yun, Thi Anh Thu, Le, Liew, Phui-Ly, Chen, Jian-Yu, Tzeng, Huey-En, Liu, Yun-Ru, Chang, Tzu-Hao, Lee, Cheng-Yang, Hung, Chin-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204905/ https://www.ncbi.nlm.nih.gov/pubmed/35715741 http://dx.doi.org/10.1186/s10020-022-00474-9 |
Ejemplares similares
-
Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction
por: Chang, Shih-Ching, et al.
Publicado: (2020) -
DEF6 expression in ovarian carcinoma correlates with poor patient survival
por: Liew, Phui-Ly, et al.
Publicado: (2016) -
Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer
por: Ansar, Muhamad, et al.
Publicado: (2022) -
Clinicopathologic and Prognostic Significance of Thymopoietin-α Overexpression in Gastric Cancer
por: Sun, Ding-Ping, et al.
Publicado: (2019) -
Frailty in chronic myeloid leukemia: evidence from 2016–2018 Nationwide Inpatient Sample of the US
por: Huan-Tze, Lin, et al.
Publicado: (2023)